BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia
William E. Pierceall(Bristol-Myers Squibb (Switzerland)), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Marina Konopleva(Albert Einstein College of Medicine), Michael H. Cardone(The Ohio State University), Nicole E. Carlson(The University of Texas MD Anderson Cancer Center), Noel Blake(The University of Texas MD Anderson Cancer Center), Ryan Lena(The University of Texas MD Anderson Cancer Center), Michael Elashoff, Xuelin Huang(The University of Texas MD Anderson Cancer Center), Steven M. Kornblau(The University of Texas MD Anderson Cancer Center)
Cited by 32
Related Papers
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|627